Sub menu
Open Close
 
 

What is Swelife?

Swelife is a strategic innovation programme, funded by the Swedish Government via the Swedish innovation agency, Vinnova, and by the programme’s collaborative partners in healthcare, academia and industry. Swelife’s goal is to strengthen Swedish Life Science and improve public health. 

By challenging obstacles and stimulating and supporting new national solutions for innovation, Swelife’s work is to contribute to

1) the development, utilisation and evaluation of innovations in healthcare, as well as to personalised and values-based medical practice

2) making Swedish Life Science attractive and internationally competitive.

Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

Our vision

Life Science in Sweden will take the lead to generate world-class health and sustainable growth through innovation and collaboration.

Our mission

Swelife facilitates and accelerates innovation and collaboration in Life Science – from ideas to societal benefits.

OUR ROLE

Sweden already has a crowded and complex map of actors in Life Science. What role does Swelife play in all of this? What can we bring to the table? This is how we see it:

Swelife is

  • a national innovation programme, funded by the Swedish Government via the Swedish innovation agency, Vinnova, and by the programme’s collaborative partners
  • a national facilitator for healthcare, academia and industry

Our approach

  • Swelife identifies, calls attention to and challenges obstacles for innovation
  • Swelife stimulates and supports new national solutions

Budget and support

More than 100 organisations from healthcare, academia and industry in Sweden currently support Swelife.

Budget

  • 2017: SEK 55 million from Vinnova (+SEK 55 million in co-financing)
  • 2016: SEK 40 million from Vinnova (+SEK 40 million in co-financing)
  • 2015: SEK 30 million from Vinnova (+SEK 30 million in co-financing)
  • 2014: SEK 9 million from Vinnova (+SEK 9 million in co-financing)
  • 2016–2019: some SEK 50 million from European structural funds (ERUF funding) through the Swedish Agency for Economic and Regional Growth.

The budget for 2018–2020 will be decided by Vinnova after an evaluation of Swelife in 2017.

HISTORY

Swelife was established in the summer of 2014 when the Diabetes Agenda and SILS (Sweden as an International Centre for Life Science) jointly applied to launch a so-called strategic innovation area (SIO). The idea was to gather the Life Science regions in Sweden under one common national research and innovation agenda.

The SIO on non-communicable diseases was approved in May 2014, changed its name to Swelife in the autumn, and in January 2015 included an additional agenda (PMC – Personalised Medicine Cancer).

For a competitive life science ecosystem in Sweden

With support from: